{"id":"treatment-with-dorzolamide-timolol","safety":{"commonSideEffects":[{"rate":"25-33","effect":"Ocular burning or stinging"},{"rate":"15-20","effect":"Blurred vision"},{"rate":"10-15","effect":"Tearing"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Bitter taste"},{"rate":"5","effect":"Allergic conjunctivitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide decreases aqueous humor production by inhibiting carbonic anhydrase II in the ciliary body, while timolol reduces aqueous humor production and increases uveoscleral outflow through non-selective beta-adrenergic receptor antagonism. Together, these complementary mechanisms provide additive intraocular pressure reduction.","oneSentence":"Dorzolamide/timolol is a fixed-dose combination that reduces intraocular pressure by inhibiting carbonic anhydrase (dorzolamide) and blocking beta-adrenergic receptors (timolol).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:17.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07335211","phase":"PHASE3","title":"Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2026-01","conditions":"Primary Open Angle Glaucoma (POAG), Ocular Hypertension","enrollment":206},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT05973318","phase":"PHASE3","title":"Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL","status":"COMPLETED","sponsor":"Jadran Galenski laboratorij d.d.","startDate":"2017-04-10","conditions":"Primary Open Angle Glaucoma of Both Eyes","enrollment":110},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT05083689","phase":"PHASE2, PHASE3","title":"Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-10-06","conditions":"Diabetic Macular Edema","enrollment":62},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT03034772","phase":"PHASE2, PHASE3","title":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-02-08","conditions":"Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":52},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03257813","phase":"PHASE3","title":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2016-04-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT02571972","phase":"PHASE2","title":"Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2015-02-01","conditions":"Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema","enrollment":14},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT01062971","phase":"PHASE2","title":"Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2006-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":124},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT01843920","phase":"NA","title":"The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble","status":"COMPLETED","sponsor":"Jason Hsu, MD","startDate":"2011-06","conditions":"Scleral Buckling","enrollment":21},{"nctId":"NCT00832377","phase":"PHASE2","title":"COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-24","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT01228149","phase":"PHASE4","title":"COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy","status":"COMPLETED","sponsor":"Katrin Lorenz","startDate":"2010-08","conditions":"Glaucoma","enrollment":62},{"nctId":"NCT00545064","phase":"PHASE4","title":"Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05-23","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":176},{"nctId":"NCT00906087","phase":"PHASE4","title":"Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2009-08-04","conditions":"Glaucoma","enrollment":14},{"nctId":"NCT00546286","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":170},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT01471158","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Glaucoma","enrollment":120},{"nctId":"NCT00906594","phase":"PHASE4","title":"Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-09","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00972257","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-01","conditions":"Glaucoma","enrollment":64},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01923714","phase":"","title":"Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-08","conditions":"Open Angle Glaucoma","enrollment":103},{"nctId":"NCT01284166","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00471068","phase":"PHASE4","title":"Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT01304264","phase":"","title":"Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2011-03","conditions":"Open Angle Glaucoma","enrollment":35},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00822081","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2005-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00804115","phase":"NA","title":"The International Collaborative Exfoliation Syndrome Treatment Study","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2000-08","conditions":"Exfoliation Syndrome, Glaucoma, Ocular Hypertension","enrollment":277}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":219,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"treatment with dorzolamide/timolol","genericName":"treatment with dorzolamide/timolol","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dorzolamide/timolol is a fixed-dose combination that reduces intraocular pressure by inhibiting carbonic anhydrase (dorzolamide) and blocking beta-adrenergic receptors (timolol). Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}